MX2022003507A - Modulos de union que comprenden dominios ehd2 modificados. - Google Patents

Modulos de union que comprenden dominios ehd2 modificados.

Info

Publication number
MX2022003507A
MX2022003507A MX2022003507A MX2022003507A MX2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A
Authority
MX
Mexico
Prior art keywords
modified
binding molecules
binding modules
ehd2
ehd2 domains
Prior art date
Application number
MX2022003507A
Other languages
English (en)
Inventor
Roland Kontermann
Oliver Seifert
Original Assignee
Univ Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Stuttgart filed Critical Univ Stuttgart
Publication of MX2022003507A publication Critical patent/MX2022003507A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a moléculas de unión que comprenden dos cadenas polipeptídicas, en las que las cadenas peptídicas comprenden dominios EHD2 modificados que permiten solo la heterodimerización, evitando así los homodímeros, los ácidos nucleicos que codifican dichas moléculas de unión y los usos de dichas moléculas de unión o ácidos nucleicos que codifican dichas moléculas de unión en terapia.
MX2022003507A 2019-09-25 2020-09-25 Modulos de union que comprenden dominios ehd2 modificados. MX2022003507A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19199639 2019-09-25
PCT/EP2020/077008 WO2021058804A1 (en) 2019-09-25 2020-09-25 Binding modules comprising modified ehd2 domains

Publications (1)

Publication Number Publication Date
MX2022003507A true MX2022003507A (es) 2022-04-25

Family

ID=68109107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003507A MX2022003507A (es) 2019-09-25 2020-09-25 Modulos de union que comprenden dominios ehd2 modificados.

Country Status (9)

Country Link
US (1) US20220372147A1 (es)
EP (1) EP4034244A1 (es)
JP (1) JP2022550316A (es)
KR (1) KR20220071210A (es)
CN (1) CN115066275A (es)
AU (1) AU2020356407A1 (es)
CA (1) CA3155725A1 (es)
MX (1) MX2022003507A (es)
WO (1) WO2021058804A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
SG172754A1 (en) * 2008-10-10 2011-08-29 Trubion Pharmaceuticals Inc Tcr complex immunotherapeutics
LT2519543T (lt) * 2009-12-29 2016-10-10 Emergent Product Development Seattle, Llc Heterodimerus rišantys baltymai ir jų panaudojimas
WO2013075027A2 (en) * 2011-11-17 2013-05-23 Emergent Product Development Seattle, Llc Anti-sil6xr complex binding domains and methods of use
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof

Also Published As

Publication number Publication date
AU2020356407A1 (en) 2022-04-07
US20220372147A1 (en) 2022-11-24
EP4034244A1 (en) 2022-08-03
WO2021058804A1 (en) 2021-04-01
JP2022550316A (ja) 2022-12-01
KR20220071210A (ko) 2022-05-31
CN115066275A (zh) 2022-09-16
CA3155725A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
MX2023003630A (es) Aglutinantes de albumina de suero mejorados.
MX2023005374A (es) Aglutinantes de albumina serica mejorados.
PH12018502182A1 (en) Trispecific and/or trivalent binding proteins
MX2019008536A (es) Aglutinantes de albumina serica mejorados.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
BR112017019862A2 (pt) modulação de imunidade de tumor através de liberaçâo de o2 mediada por proteína
PH12018501025A1 (en) Improved tnf binders
PH12019500596A1 (en) Recombinant binding proteins and their use
WO2017085172A3 (en) Improved serum albumin binders
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
MX2016012880A (es) Cadena j modificada.
NZ603570A (en) Biological materials related to her3
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
NZ759601A (en) Aggrecan binding immunoglobulins
WO2015166105A3 (en) Ion channel modulators and uses thereof
MX2016006277A (es) Secuencia de endolisina kz144 modificada.
MX2019014400A (es) Inmunoglobulinas que se unen a adamts.
MX2023004804A (es) Proteinas de union triespecificas y/o trivalentes.
MX2022007919A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
MX2022003507A (es) Modulos de union que comprenden dominios ehd2 modificados.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
MX2021011854A (es) Tratamiento conjunto antineoplasico.
MX2022000725A (es) Anticuerpos potenciadores del factor h y usos de estos.
BR112022001695A2 (pt) Receptores de células t e métodos de uso dos mesmos
TN2018000345A1 (en) Trispecific and/or trivalent binding proteins